Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports

Table 1 Baseline demographics prior to sofosbuvir/velpatasvir/voxilaprevir therapy

Patient No.	Age/Sex	Race	HCC	Decompensated cirrhosis	HCV RNA (IU/L)	Downstaged within Milan criteria	Within Milan criteria on explant
1	51 M	AA	Yes	No	27461835	Yes	Yes
2	68 M	O	Yes	No	944857	Yes	No
3	66 M	AA	Yes	Yes	894000	No	Yes
4	70 M	AA	Yes	No	14700000	No	Yes
5	48 M	AA	Yes	Yes	3150000	No	Yes
6	68 F	AA	Yes	No	9024158	1	1

¹Liver transplant was performed at another hospital and pathology records were not available.

AA: African American; O: Identified as “other” race; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HCV RNA: Hepatitis C RNA viral load before sofosbuvir/velpatasvir/voxilaprevir therapy; Milan criteria: Did explant pathology satisfy Milan criteria.